Induction Of Interleukin Research Articles

85. Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients

Abstract Background Various pre-clinical and clinical studies suggest an interplay between complement C5a/C5a receptor (R1) and interleukin 6 (IL-6) signaling. C5a boosts IL-6 levels and IL-6 increases C5aR1 in inflammation and sepsis models (Fig 1). Blocking IL-6 signaling, e.g. with tocilizumab (Toci), in patients with acute coronary artery disease and with antibodies in pre-clinical studies in different tissues significantly reduces C5aR1 expression. In addition, inhibiting C5a with vilobelimab (Vilo) in COVID-19 patients with acute respiratory distress syndrome (ARDS) also improves survival as shown in a multicenter, double-blind, randomized, placebo-controlled, phase 3 trial (PANAMO, NCT04333420). COVID-19 patients with ARDS who receive Toci in addition to Vilo may serve as a model for the interplay between IL-6 and the C5a/C5aR1 axis to improve survival in ARDS.Figure 1:C5a induction of IL-6 and IL-6 induction of C5aR1. Induction of IL-6 is blocked by vilobelimab binding to C5a and tocilizumab blocks IL-6 binding to IL-6 receptor decreasing induction of C5aR1. Methods COVID-19 patients with ARDS in the Phase III PANAMO study (N=368) received up to six Vilo 800mg infusions or placebo (Plc) plus corticosteroids and anticoagulants (standard-of-care) within 48 hours of intubation over a 22-day period. A post-hoc Cox regression analysis was performed for 28- and 60-Day all-cause mortality in a subgroup of patients (n=60) who also received prior (within -7 days of Vilo administration) or concomitant Toci. Safety was also assessed.Figure 2:Kaplan Meier Survival Curve of COVID-19 Patients with ARDS Treated with Tocilizumab (Toci) prior (within 7 days) of Vilobelimab+SOC and Placebo+SOC. SOC= Standard-of-Care; corticosteroids and anticoagulants. Results Vilo+Toci (n=29) and Plc+Toci (n=31) showed point estimates for 28-Day all-cause mortality of 3.7% and 42.3% (HR 0.073; 95%CI:0.01-0.56, p=0.012), while 60-Day all-cause mortality point estimates were 15.9% and 49.1% (HR 0.245; 95%CI:0.08-0.74, p=0.013), respectively (Fig 2). Related TEAEs were similar in both groups (28.6% vs 25.8%). Serious TEAEs occurred in fewer patients receiving Vilo+Toci (42.9%) vs Plc+Toci (67.7%). Infections and infestations were slightly lower for Vilo+Toci (53.6%) vs Plc+Toci (64.5%). Conclusion This post-hoc analysis demonstrated that dual immunomodulator inhibition of the C5a/C5aR1 axis and IL-6 signaling improved survival in a subgroup of COVID-19 patients with ARDS without impacting safety. Dual immunomodulator treatment with vilobelimab and tocilizumab could potentially be used in different ARDS populations to produce a similar effect. Larger and well-controlled studies are warranted to test this hypothesis. Disclosures Roy F. Chemaly, MD/MPH, AiCuris: Advisor/Consultant|AiCuris: Grant/Research Support|Ansun Pharmaceuticals: Advisor/Consultant|Ansun Pharmaceuticals: Grant/Research Support|Astellas: Advisor/Consultant|Eurofins-Viracor: Grant/Research Support|InflaRX: Advisor/Consultant|Janssen: Advisor/Consultant|Karius: Advisor/Consultant|Karius: Grant/Research Support|Merck/MSD: Advisor/Consultant|Merck/MSD: Grant/Research Support|Moderna: Advisor/Consultant|Oxford Immunotec: Advisor/Consultant|Oxford Immunotec: Grant/Research Support|Roche/Genentech: Advisor/Consultant|Roche/Genentech: Grant/Research Support|Shinogi: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Grant/Research Support|Tether: Advisor/Consultant Alexander Vlaar, MD, PhD, InflaRx GmbH: Advisor/Consultant Bruce P. Burnett, PhD, InflaRx Pharmaceuticals, InflaRx GmbH: Employee Camilla Chong, MD, InflaRx GmbH: Employee simon Rückinger, PhD, InflaRx GmbH: Advisor/Consultant Robert Zerbib, MSc, InflaRx GmbH: Advisor/Consultant Raymond M. Panas, PhD, InflaRx Pharmaceuticals, InflaRx GmbH: Employee Renfeng Guo, MD, InflaRx GmbH: Board Member|InflaRx GmbH: Chief Scientific Officer|InflaRx GmbH: Ownership Interest|InflaRx GmbH: Stocks/Bonds (Public Company) Niels Riedemann, MD, PhD, InflaRx GmbH: Board Member|InflaRx GmbH: Chief Executive Officer|InflaRx GmbH: Ownership Interest|InflaRx GmbH: Stocks/Bonds (Public Company) Diederik van de Beek, MD, PhD, InflaRx GmbH: Advisor/Consultant

The role of cellular senescence in aortic dissection

Abstract Background Aortic dissection (AD) is a catastrophic disease with high mortality. Survived patients frequently suffer from serious complications due to progressive destruction of the aortic walls. Recently we have reported that cell proliferation precedes the inflammatory response which is important in AD development and progression. Since cell proliferation promotes cellular senescence that can induce inflammatory response through SASP (senescence-associated secretary phenotype), we hypothesized that cellular senescence plays a critical role in AD pathogenesis. Purpose To investigate if cellular senescence contributes to AD pathogenesis in mouse AD model. Methods and Results A mouse AD model was created by the continuous infusion of beta-aminopropionitrile and angiotensin II (BAPN+AngII) for 14days. BAPN+AngII infusion induced senescence markers and senescent cells in mouse AD model. Senescent cells, as demonstrated by the expression of senescence-associated beta-galactosidase, were evident in intimal endothelial cells, medial smooth muscle cells, adventitial macrophages, and fibroblasts. Rapamycin, an inhibitor of mTOR pathway, suppressed the expression of senescent cells on the aortic tissue and the senescent marker protein expression. To examine the role of cellular senescence in AD, we orally administrated ABT263 known as "senolytics" that eliminates senescent cells. ABT263 treatment prevented cellular senescence in mouse AD model. The AD mortality of ABT263 group was 35%, which was lower than that of vehicle group (66.7%, P < 0.05 by log-rank test). The severity of AD, as assessed by the lesion length in vehicle group was 33.2 ± 3.1mm, whereas that in ABT263 group was 24.6 ± 1.8mm (P < 0.05). Transcriptome analysis revealed that ABT263 treatment suppressed the immune and inflammatory response in the aorta before AD onset. Quantitative RT-PCR confirmed that ABT263 treatment prevented the induction of p21Cip1, interleukin-6, several chemokines and M1 macrophage marker CD80 and CD86. It is known that Jnk activation induces SASP and accelerates cellular senescence. Western blotting confirmed that ABT263 reduced the ratio of pJnk to total Jnk, which was induced by BAPN + AngⅡ. Moreover, aortic smooth muscle cells（SMCs）remained contractile phenotype in ABT263 group, whereas BAPN+AngII reduced that phenotype in vehicle group. Conclusions Cell proliferation via mTOR pathway causes cellular senescence in mouse AD model. Jnk activation was confirmed in mouse AD model. Cellular senescence contributes to AD progression and death associated with inflammatory responses including SASP, the differentiation to M1 macrophage, and the phenotype change of SMCs.Cellular senescence represents a potential predictor and a therapeutic target for AD.

Effects of fermentation conditions (salt concentration, temperature, and pH) on Lactobacillus strains for induction of interleukin-12 in the exposed murine splenocytes

The present work aimed to assess the stresses of temperature, salt concentration, and pH on Lactobacillus gasseri 54C, Lactiplantibacillus plantarum ATCC 14917, and 11SH in fermented culture medium and their effects on interleukin-12 (IL-12) induction in murine splenocytes. First, the strains were fermented under different microbial stress conditions at salt concentrations (2, 4, and 6 % w/v), temperatures (30 and 42 °C), and pH levels (4, 5, and 6), as well as their combined conditions. Then, they were heat-killed, lyophilized, and exposed to murine splenocytes. The IL-12 induction was measured using the immunoassay method. It was indicated that the induction of IL-12 depended on the culture conditions, as it was increased by the fermentation strains under microbial stresses with the higher temperature (42 °C), lower salt concentration (%2), and lower pH level (4). It seems that the bacterial cells' integrity is essential to stimulate the induction of IL-12.

Inflammasomes primarily restrict cytosolic Salmonella replication within human macrophages.

Salmonella enterica serovar Typhimurium is a facultative intracellular pathogen that utilizes its type III secretion systems (T3SSs) to inject virulence factors into host cells and colonize the host. In turn, a subset of cytosolic immune receptors respond to T3SS ligands by forming multimeric signaling complexes called inflammasomes, which activate caspases that induce interleukin-1 (IL-1) family cytokine release and an inflammatory form of cell death called pyroptosis. Human macrophages mount a multifaceted inflammasome response to Salmonella infection that ultimately restricts intracellular bacterial replication. However, how inflammasomes restrict Salmonella replication remains unknown. We find that caspase-1 is essential for mediating inflammasome responses to Salmonella and restricting bacterial replication within human macrophages, with caspase-4 contributing as well. We also demonstrate that the downstream pore-forming protein gasdermin D (GSDMD) and Ninjurin-1 (NINJ1), a mediator of terminal cell lysis, play a role in controlling Salmonella replication in human macrophages. Notably, in the absence of inflammasome responses, we observed hyperreplication of Salmonella within the cytosol of infected cells as well as increased bacterial replication within vacuoles, suggesting that inflammasomes control Salmonella replication primarily within the cytosol and also within vacuoles. These findings reveal that inflammatory caspases and pyroptotic factors mediate inflammasome responses that restrict the subcellular localization of intracellular Salmonella replication within human macrophages.

In vivo overexpression of the avian interleukin-17 in a necrotic enteritis disease model modulates the expression of antimicrobial peptides in the small intestine of broilers

In humans and mice, the induction of interleukin (IL)-17 expression enhances epithelial barrier integrity through the secretion of antimicrobial peptides (AMP), thereby improving antibacterial defense. However, it is unclear whether IL-17 has similar antibacterial effects in chickens by modulating the expression of AMPs, such as avian beta-defensins (also known as gallinacins) and cathelicidins. This study evaluated the in vivo effects of inoculating 20-day-old broiler chickens with two doses of a plasmid encoding chicken IL-17 (pCDNA3.1/rchIL-17-V5-HIS TOPO plasmid [pCDNA3.1-IL-17]; 5 or 10 μg/bird). On day 23 of age, all broilers, except those in the negative control group, were orally challenged with a virulent Clostridium perfringens strain for three days. To investigate IL-17-mediated effects against C. perfringens infection, the expression of avian beta-defensin 1 (avBD1), avBD2, avBD4, avBD6, cathelicidins, and inducible nitric oxide synthase (iNOS) genes were quantified, and gross necrotic enteritis (NE) lesion scores were assessed in the small intestine. The results showed that broilers receiving the higher dose of pCDNA3.1-IL-17 (10 μg) had significantly lower NE lesion scores compared to those receiving the lower dose (5 μg), the vector control, and the positive control groups. Furthermore, the expression of all avian beta-defensins and cathelicidin genes was detectable across all groups, regardless of treatment and time points. IL-17 treatment led to significantly higher expression of avBD1, avBD2, avBD4, avBD6, cathelicidin, and iNOS in the duodenum, jejunum, and ileum compared to control chickens. In C. perfringens-infected chickens, the expression of avBD1, avBD2, avBD4, cathelicidin, and iNOS in the ileum was significantly higher than in control chickens. Pre-treatment with the higher dose of pCDNA3.1-IL-17 (10 μg) in infected chickens was associated with reduced NE lesion severity and increased expression of avBD1, avBD2, cathelicidin, and iNOS in the ileum, but not avBD4 and avBD6. These findings provide new insights into the potential effect of IL-17 and reduction in NE lesion severity by modulating AMP expression which may be involved in mediating protective immunity against intestinal infection with C. perfringens.

CPT1A-IL-10-mediated macrophage metabolic and phenotypic alterations ameliorate acute lung injury.

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a common acute respiratory failure due to diffuse pulmonary inflammation and oedema. Elaborate regulation of macrophage activation is essential for managing this inflammatory process and maintaining tissue homeostasis. In the past decades, metabolic reprogramming of macrophages has emerged as a predominant role in modulating their biology and function. Here, we observed reduced expression of carnitine palmitoyltransferase 1A (CPT1A), a key rate-limiting enzyme of fatty acid oxidation (FAO), in macrophages of lipopolysaccharide (LPS)-induced ALI mouse model. We assume that CPT1A and its regulated FAO is involved in the regulation of macrophage polarization, which could be positive regulated by interleukin-10 (IL-10). After nasal inhalation rIL-10 and/or LPS, wild type (WT), IL-10-/-, Cre-CPT1Afl/fl and Cre+CPT1Afl/fl mice were sacrificed to harvest bronchoalveolar lavage fluid, blood serum and lungs to examine cell infiltration, cytokine production, lung injury severity and IHC. Bone marrow-derived macrophages (BMDMs) were extracted from mice and stimulated by exogenous rIL-10 and/or LPS. The qRT-PCR, Seahorse XFe96 and FAO metabolite related kits were used to test the glycolysis and FAO level in BMDMs. Immunoblotting assay, confocal microscopy and fluorescence microplate were used to test macrophage polarization as well as mitochondrial structure and function damage. In in vivo experiments, we found that mice lacking CPT1A or IL-10 produced an aggravate inflammatory response to LPS stimulation. However, the addition of rIL-10 could alleviate the pulmonary inflammation in mice effectively. IHC results showed that IL-10 expression in lung macrophage decreased dramatically in Cre+CPT1Afl/fl mice. The in vitro experiments showed Cre+CPT1Afl/fl and IL-10-/- BMDMs became more "glycolytic", but less "FAO" when subjected to external attacks. However, the supplementation of rIL-10 into macrophages showed reverse effect. CPT1A and IL-10 can drive the polarization of BMDM from M1 phenotype to M2 phenotype, and CPT1A-IL-10 axis is also involved in the process of maintaining mitochondrial homeostasis. CPT1A modulated metabolic reprogramming and polarisation of macrophage under LPS stimulation. The protective effects of CPT1A may be partly attributed to the induction of IL-10/IL-10 receptor expression.

Macrophage-fibroblast crosstalk drives Arg1-dependent lung fibrosis via ornithine loading.

Monocyte-derived macrophages recruited to injured tissues induce a maladaptive fibrotic response characterized by excessive production of collagen by local fibroblasts. Macrophages initiate this programming via paracrine factors, but it is unknown whether reciprocal responses from fibroblasts enhance profibrotic polarization of macrophages. We identify macrophage-fibroblast crosstalk necessary for injury-associated fibrosis, in which macrophages induced interleukin 6 ( IL-6 ) expression in fibroblasts via purinergic receptor P2rx4 signaling, and IL-6, in turn, induced arginase 1 ( Arg1 ) expression in macrophages. Arg1 contributed to fibrotic responses by metabolizing arginine to ornithine, which fibroblasts used as a substrate to synthesize proline, a uniquely abundant constituent of collagen. Imaging of idiopathic pulmonary fibrosis (IPF) lung samples confirmed expression of ARG1 in myeloid cells, and arginase inhibition suppressed collagen expression in cultured precision-cut IPF lung slices. Taken together, we define a circuit between macrophages and fibroblasts that facilitates cross-feeding metabolism necessary for injury-associated fibrosis.

Methoxylated Flavones from Casimiroa edulis La Llave Suppress MMP9 Expression via Inhibition of the JAK/STAT3 Pathway and TNFα-Dependent Pathways.

Matrix metalloproteinase 9 (MMP9), an MMP isozyme, plays a crucial role in tumor progression by degrading basement membranes. It has therefore been proposed that the pharmacological inhibition of MMP9 expression or activity could inhibit tumor metastasis. We previously isolated two novel methoxylated flavones, casedulones A and B, from the leaves and/or roots of Casimiroa edulis La Llave and determined that these casedulones have antitumor activity that acts via the reduction of MMP9. Here, we examined how these casedulones suppress lipopolysaccharide (LPS)-induced MMP9 expression in human monocytic THP-1 cells. The casedulones suppressed the LPS-induced signal transducer and activator of transcription 3 (STAT3) pathway, which participates in MMP9 induction. In addition, AG490 and S3I-201, inhibitors of Janus kinase (JAK) and STAT3, suppressed LPS-mediated MMP9 induction, suggesting that the casedulones suppressed MMP9 induction through the inhibition of JAK/STAT3 pathways. Based on the findings that cycloheximide, an inhibitor of de novo protein synthesis, completely inhibited LPS-mediated MMP9 induction, the role of de novo proteins in MMP9 induction was further investigated. We found that the casedulones inhibited the induction of interleukin-6 (IL-6), a key inflammatory cytokine that participates in STAT3 activation. Moreover, tumor necrosis factor-α (TNFα)-mediated MMP9 induction was significantly suppressed in the presence of the casedulones. Taken together, these findings suggest that casedulones inhibit the IL-6/STAT3 and TNFα pathways, which all involve LPS-mediated MMP9 induction.

Serum Proteins Infer Molecular Protection Against Inflammation in Weddell Seal (Leptonychotes weddellii) Blood

Weddell seals ( Leptonychotes weddellii) are elite divers able to dive up to 900 meters deep and remain submerged for over 90 minutes. Weddell seals have a dramatic dive response to allow for longer, deeper dives including intense bradycardia and constriction of blood vessels, especially those supplying peripheral or visceral organs. Vasoconstriction, hypo-perfusion and subsequent re-oxygenation upon surfacing is known to induce tissue injury in terrestrial mammals via inflammation. Previous work interrogating the Weddell seal’s innate immune system suggested a component in the seal’s blood serum that protects against inflammation. We are using a mouse macrophage (RAW 264.7) cell model to characterize components of the seal’s blood that are anti-inflammatory to lipopolysaccharide (LPS). When exposed to 10 ng/mL LPS, RAW cells supplemented with deproteinated serum from adult Weddell seals lose their protection against inflammation, having 11-fold greater induction of interleukin-6 (IL-6) mRNA expression after a 6-h exposure compared to RAW cells supplemented with intact seal serum (T=3.29, p=0.01). To determine whether anti-inflammatory capacity of serum is innately present in Weddell seals or whether it is acquired in conjunction with development of diving capacity, we compared the protective effects of adult Weddell seal serum against serum from Weddell seal pups collected at approximately their age of weaning, when they had begun diving activities but do not yet dive deep. Following exposure to 10 ng/mL LPS, IL-6 expression was 69% lower in RAW cells supplemented with serum from adult seals compared to those supplemented with serum from pups (T=8.41, p=0.002), suggesting that ontogeny or diving behavior contributes to the development of anti-inflammatory serum. Analysis of adult (n=12) and pup (n=11) serum proteomes revealed a single protein, colony stimulating factor 2 receptor subunit beta (CSF2RB), with a 24-fold higher abundance in adults (PFDR<0.0001). CSF2RB is a pleiotropic cell surface receptor subunit with known functions in innate immunity, erythropoiesis, as well as tissue protection. Therefore, we hypothesize that it plays a role in the anti-inflammatory protection observed in adult seals. Defining the mechanism of action for this protein in seal serum could identify a protective adaptation that facilitates deep and long dives. In a broader context, lessons learned from an extreme diving mammals may identify anti-inflammatory strategies with new clinical relevance. NSF #1921491; #1853326; #2337400. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Abstract 729: IDO1 inhibition enables IFNγ-elicited responsiveness of pulmonary breast cancer metastases to hypoxia-directed tumoricidal agents

Abstract In mouse models of lung carcinoma and pulmonary breast cancer metastasis, genetic ablation of the tryptophan catabolizing enzyme IDO1 (indoleamine 2,3-dioxygenase 1) resulted in restricted tumor outgrowth associated with attenuated induction of the inflammatory cytokine IL6 (interleukin 6). Utilizing the 4T1 breast cancer metastasis model to further elucidate the mechanistic basis underlying IDO1’s pro-tumor activity in the lungs established that IDO1 acts as an integral determinant of a tumor-promoting inflammatory state that supports neovascular retention. Ido1−/− (nullizygous) mice exhibited impaired pulmonary metastases neovascularization and outgrowth that was driven by IFNγ (interferon gamma) in the absence of IDO1-dependent IL6 production. Hypoxia was likewise elevated, and these stress conditions increased the susceptibility of the metastatic tumor cells to cytotoxicity associated with administration of GSK2656157, an inhibitor of PERK (protein kinase RNA-like ER kinase), which acts as a primary sensor for activating the UPR (unfolded protein response) survival pathway. In WT (wild type) mice with established 4T1 lung metastases, administration of the IDO1 inhibitors epacadostat, navoximod or indoximod each similarly resulted in rapid collapse of the metastatic tumor neovasculature and concomitantly increased intratumoral hypoxia and sensitivity to PERK inhibition. Therefore, while IDO1 inhibition does not directly promote effective tumor cell killing in this context, the disruption of blood supply due to IFNγ-mediated neovascular regression subjects the tumor cells to hypoxic environmental stress, raising the possibility for therapeutic intervention with selectively targeted agents. Combining chemotherapy with immune checkpoint blockade (ICB) is recognized as an effective strategy for treating lung cancer, with first-line therapy for some patients including the alkylating agent carboplatin in conjunction with pembrolizumab. The challenge remains, however, that chemotherapy causes systemic side effects that can negatively impact quality of life and limit efficacy. Evofosfamide is an alkylating prodrug that was designed to be selectively activated in regions of hypoxia, thereby limiting systemic exposure. We report that enhanced metastatic tumor cell killing with evofosfamide can be achieved by co-administration of an IDO1 inhibitor. Elevated intratumoral hypoxia has also previously been linked to increased expression levels of PDL1, a favorable indicator of ICB responsiveness, and we have confirmed the upregulation of PDL1 in 4T1 lung metastases following IDO1 inhibitor administration. Our data in the lung metastasis model support future studies to evaluate whether IDO1 inhibition can be effectively combined with evofosfamide and anti-PD1 treatment to improve therapeutic outcomes. Citation Format: Shih-Chun Shen, Souvik Dey, James B. DuHadaway, Erika Sutanto-Ward, George C. Prendergast, Alexander J. Muller. IDO1 inhibition enables IFNγ-elicited responsiveness of pulmonary breast cancer metastases to hypoxia-directed tumoricidal agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 729.

Engineered extracellular vesicles carrying let-7a-5p for alleviating inflammation in acute lung injury

BackgroundAcute lung injury (ALI) is a life-threatening respiratory condition characterized by severe inflammation and lung tissue damage, frequently causing rapid respiratory failure and long-term complications. The microRNA let-7a-5p is involved in the progression of lung injury, inflammation, and fibrosis by regulating immune cell activation and cytokine production. This study aims to use an innovative cellular electroporation platform to generate extracellular vesicles (EVs) carring let-7a-5p (EV-let-7a-5p) derived from transfected Wharton’s jelly-mesenchymal stem cells (WJ-MSCs) as a potential gene therapy for ALI.MethodsA cellular nanoporation (CNP) method was used to induce the production and release of EV-let-7a-5p from WJ-MSCs transfected with the relevant plasmid DNA. EV-let-7a-5p in the conditioned medium were isolated using a tangential flow filtration (TFF) system. EV characterization followed the minimal consensus guidelines outlined by the International Society for Extracellular Vesicles. We conducted a thorough set of therapeutic assessments, including the antifibrotic effects using a transforming growth factor beta (TGF-β)-induced cell model, the modulation effects on macrophage polarization, and the influence of EV-let-7a-5p in a rat model of hyperoxia-induced ALI.ResultsThe CNP platform significantly increased EV secretion from transfected WJ-MSCs, and the encapsulated let-7a-5p in engineered EVs was markedly higher than that in untreated WJ-MSCs. These EV-let-7a-5p did not influence cell proliferation and effectively mitigated the TGF-β-induced fibrotic phenotype by downregulating SMAD2/3 phosphorylation in LL29 cells. Furthermore, EV-let-7a-5p regulated M2-like macrophage activation in an inflammatory microenvironment and significantly induced interleukin (IL)-10 secretion, demonstrating their modulatory effect on inflammation. Administering EVs from untreated WJ-MSCs slightly improved lung function and increased let-7a-5p expression in plasma in the hyperoxia-induced ALI rat model. In comparison, EV-let-7a-5p significantly reduced macrophage infiltration and collagen deposition while increasing IL-10 expression, causing a substantial improvement in lung function.ConclusionThis study reveals that the use of the CNP platform to stimulate and transfect WJ-MSCs could generate an abundance of let-7a-5p-enriched EVs, which underscores the therapeutic potential in countering inflammatory responses, fibrotic activation, and hyperoxia-induced lung injury. These results provide potential avenues for developing innovative therapeutic approaches for more effective interventions in ALI.

Induction of interleukin-6 by SPZ1-mediated Wnt5a signaling boosts progression of nasopharyngeal carcinoma cells.

Nasopharyngeal carcinoma (NPC) is a common malignancy in Southeast Asia, and in the Guangxi and Guangdong provinces of China. The spermatogenic transcription factor zip 1 (SPZ1) is a member of bHLH zip family, and promotes tumorigenesis in the liver, colon and breast tissues. However, the role of SPZ1 in the progression of NPC is unclear. In this study, we found that SPZ1 mRNA and protein levels were significantly upregulated in NPC tissues compared to the normal nasopharyngeal tissues. Furthermore, SPZ1 knockdown in NPC cell lines inhibited proliferation, epithelial-mesenchymal transition, migration, and invasion in vitro, and suppressed tumorigenesis in an in vivo model. On the other hand, SPZ1 overexpression facilitated the growth of NPC cells. Mechanistically, SPZ1-driven progression of NPC is dependent on the Wnt5a/interleukin-6 (IL-6) signaling pathway. Consistent with this, IL-6 levels were significantly increased in NPC tissues and correlated positively with SPZ1 expression. Taken together, our findings suggest that SPZ1 mediates NPC progression through Wnt5a/IL-6 signaling, and the SPZ1/Wnt5a/IL-6 axis is a potential therapeutic target for NPC.

Overexpression of NLRP12 enhances macrophage immune response and alleviates herpes simplex keratitis.

Herpes simplex keratitis (HSK) is a blinding disease caused by corneal infection of Herpes simplex virus type 1 (HSV-1). Effective clearance of HSV-1 from the infected cornea is crucial for HSK management. Macrophages play an important part in the innate immune defense against viral infections. This study investigates the immunomodulatory role of NLRP12 in macrophage immune response during HSV-1 infection. NLRP12 expression post-infection was assessed in various macrophage cell lines. Overexpression of NLRP12 was achieved by lentiviral transfection, and its effect on HSV-1 replication and immune responses were examined. Mechanistic insights into the role of NLRP12 were explored using immunofluorescence and Western Blot. For in vivo studies, ocular adoptive transfer of NLRP12-overexpressing bone marrow derived macrophages (BMDMs) was performed. HSV-1 viral loads, HSK symptoms, and macrophage-mediated immune responses were investigated. A significant decrease in NLRP12 expression post-infection was observed in various macrophage cell lines. Overexpression of NLRP12 in macrophages reduced HSV-1 replication. Mechanistically, overexpression of NLRP12 triggered early and robust pyroptosis in response to HSV-1 infection, inducing interleukin (IL)-18 production and activating downstream antiviral responses through the JAK-STAT signaling pathway. In vivo, ocular adoptive transfer of NLRP12-overexpressing BMDMs to mouse corneas alleviated HSK damage and reduced HSV-1 viral loads. NLRP12-overexpressing BMDMs improved antiviral responses in the cornea and promoted the maturation of corneal-infiltrating macrophages and dendritic cells. Additionally, NLRP12-overexpressing BMDMs amplified the adaptive immune response in the submandibular draining lymph nodes. These findings highlight the role of NLRP12 in macrophage-mediated immune response against HSV-1 infection and suggest its potential for possible immunotherapy for HSK.

Interleukin-10 disrupts liver repair in acetaminophen-induced acute liver failure.

Systemic levels of the anti-inflammatory cytokine interleukin 10 (IL-10) are highest in acetaminophen (APAP)-induced acute liver failure (ALF) patients with the poorest prognosis. The mechanistic basis for this counterintuitive finding is not known, as induction of IL-10 is hypothesized to temper the pathological effects of immune cell activation. Aberrant production of IL-10 after severe liver injury could conceivably interfere with the beneficial, pro-reparative actions of immune cells, such as monocytes. To test this possibility, we determined whether IL-10 levels are dysregulated in mice with APAP-induced ALF and further evaluated whether aberrant production of IL-10 prevents monocyte recruitment and/or the resolution of necrotic lesions by these cells. Our studies demonstrate that in mice challenged with 300 mg/kg acetaminophen (APAP), a hepatotoxic dose of APAP that fails to produce ALF (i.e., APAP-induced acute liver injury; AALI), Ly6Chi monocytes were recruited to the liver and infiltrated the necrotic lesions by 48 hours coincident with the clearance of dead cell debris. At 72 hours, IL-10 was upregulated, culminating in the resolution of hepatic inflammation. By contrast, in mice treated with 600 mg/kg APAP, a dose that produces clinical features of ALF (i.e., APAP-induced ALF; AALF), IL-10 levels were markedly elevated by 24 hours. Early induction of IL-10 was associated with a reduction in the hepatic numbers of Ly6Chi monocytes resulting in the persistence of dead cell debris. Inhibition of IL-10 in AALF mice, beginning at 24 hours after APAP treatment, increased the hepatic numbers of monocytes which coincided with a reduction in the necrotic area. Moreover, pharmacologic elevation of systemic IL-10 levels in AALI mice reduced hepatic myeloid cell numbers and increased the area of necrosis. Collectively, these results indicate that during ALF, aberrant production of IL-10 disrupts the hepatic recruitment of monocytes, which prevents the clearance of dead cell debris. These are the first studies to document a mechanistic basis for the link between high IL-10 levels and poor outcome in patients with ALF.

NANOG Dominates Interleukin-6-Induced Sphere Formation in Prostate Cancer.

Identifying the dynamics of prostate tumor aggressiveness is essential to find new therapeutics for the treatment. Cancer stem cells contribute to cancer progression by promoting tumor growth and metastasis, resisting treatment, and evading the immune system. Interleukin 6 (IL-6) is a pleiotropic cytokine that functions in inflammation, immune response, etc. However, dysregulated expression of IL-6 plays a pathological role in such conditions as cancer. In this study, we aimed to elucidate the effect of IL-6 on cancer stemness genes in prostate cancer cells. Enrichment of stem-like cells was achieved through the formation of tumor spheres using the DU-145 cell line. Sphere formation was conducted in a medium supplemented with IL-6 and compared to a control group. The number of spheres was quantified, and the resulting pellet was collected for quantitative reverse transcription polymerase chain reaction analysis to assess the impact of IL-6 induction on the expression of stemness-related genes. Tumor sphere numbers and sizes increased in IL-6-induced environment. NANOG expression elevated in an IL-6-enriched environment compared to the nontreated spheres. Our results demonstrated that IL-6 induction in prostate tumor spheres upregulates NANOG gene expression. Inducing IL-6 in prostate tumor spheres stimulates stemness biomarker NANOG genes. NANOG may be suggested as a therapeutic target for metastatic prostate cancer.

The role of cellular senescence in aortic dissection

Abstract Background Aortic dissection (AD) is a catastrophic disease with high mortality. Survived patients frequently suffer from serious complications due to progressive destruction of the aortic walls. Recently we have reported that cell proliferation precedes the inflammatory response which is important in AD development and progression. Since cell proliferation promotes cellular senescence that can induce inflammatory response through SASP (senescence-associated secretary phenotype), we hypothesized that cellular senescence plays a critical role in AD pathogenesis. Purpose To investigate if cellular senescence contributes to AD pathogenesis in a mouse AD model. Methods and Results A mouse AD model was created by continuous infusion of beta-aminopropionitrile and angiotensin II (BAPN+AngII), where AD occurs to most of the mice in 14 days. BAPN+AngII challenge resulted in the appearance of senescent cells in the aortic walls before AD onset, which persisted for 14 days. Senescent cells, as demonstrated by the expression of senescence-associated beta-galactosidase, were evident in multiple types including endothelial cells, medial smooth muscle cells, adventitial macrophages and fibroblasts. Rapamycin, an inhibitor of mTOR pathway, suppressed the cell proliferation, the cellular senescence, and the development and progression of AD. To examine the role of cellular senescence in AD pathogenesis, ABT263, which is a senolytic drug that eliminates senescent cells, was administered orally to AD model mice. ABT263 treatment reduced the expression of the senescence markers. In the ABT263-treated group, the AD mortality was significantly decreased compared to that in vehicle-treated group (35% vs 67%, P < 0.05 by log-rank test). The severity of AD, as assessed by the lesion length, was also attenuated in ABT263 group (24.6 ± 1.8 mm vs 33.2 ± 3.1 mm, P < 0.05). Transcriptome analysis revealed that ABT263 treatment suppressed the aortic immune and inflammatory response induced by BAPN+AngII. Quantitative RT-PCR of aortic tissue confirmed that ABT263 treatment prevented the induction of p21, interleukin-6, several chemokines and M1 macrophage marker (CD80). ABT263 treatment suppressed CD80 expression also in cultured macrophages. Conclusions These results indicated that cell proliferation and senescence via mTOR pathway are critically involved in AD pathogenesis. Cellular senescence contributes to the inflammatory response including M1 differentiation of macrophages, and to the severity and the mortality in AD. Cellular senescence could be a new therapeutic target for AD.

Abstract 12710: The Role of Cellular Senescence in Aortic Dissection

Background: Aortic dissection (AD) is a catastrophic disease with high mortality and serious complications, and its molecular pathogenesis is largely unknown. The importance of inflammation in AD has been reported. Recently we found that cell proliferation precedes the inflammatory response in AD. Cell proliferation causes cellular senescence that induces inflammatory response, however, role of cellular senescence in AD has not been elucidated. Objective: We investigated if cellular senescence contributes to AD pathogenesis in mouse AD model. Methods and Results: A mouse AD model was created by continuous infusion of beta-aminopropionitrile and angiotensin II (BAPN+AngII) for 14days. BAPN+AngII infusion induced senescence markers from day 3, before AD onset, and persisted until day14. Senescent cells, as demonstrated by the expression of senescence-associated beta-galactosidase, were evident in intimal endothelial cells, medial smooth muscle cells, adventitial macrophages, and fibroblasts. To examine role of cellular senescence in AD, we orally administrated ABT263 known as “senolytics” that eliminates senescent cells. ABT263 treatment reduced the expression of the senescence markers. The AD mortality of ABT263 group was 35%, which was lower than that of vehicle group(66.7%, P < 0.05 by log-rank test). The severity of AD, as assessed by the lesion length in vehicle group was 33.2 ± 3.1mm, whereas that in ABT263 group was 24.6 ± 1.8mm (P < 0.05). Transcriptome analysis revealed that ABT263 treatment suppressed the immune and inflammatory response in the aorta before AD onset. Quantitative RT-PCR confirmed that ABT263 treatment prevented the induction of p21Cip1, interleukin-6 and several chemokines. Bioplex analysis of mice’s serum showed that ABT263 decreased inflammatory molecules in mice’s serum compared to vehicle group. Moreover, aortic smooth muscle cells(SMCs)remained contractile phenotype in ABT263 group, whereas BAPN+AngII reduced the phenotype in vehicle group. Conclusions: Elimination of senescent cells prevented AD progression and death in mice. ABT263 suppressed the inflammatory response and contributed to retain the SMCs phenotype. Cellular senescence represents a potential predictor and a therapeutic target for AD.

Hypoxic mesenchymal stem cells (MSCS)-induced interleukin (IL)-10 alleviate systemic lupus erythematosus (SLE) infl ammation through inhibiting interferon (IFN)-gamma production

<p><strong>Aim</strong> <br />To determine the eff ect of hypoxic mesenchymal stem cells (MSCs) on the interleukin (IL)-10 and interferon (IFN)-gamma in peripheral blood mononuclear cells (PBMCs) from systemic lupus erythematosus (SLE) patients.<br /><strong>Methods</strong> <br />This study used a post-test control group design. Hypoxic MSCs were isolated and characterized according to their surface marker expression and diff erentiation capacities. PBMCs isolated from SLE patients were divided into three groups: control and two treatment groups. The treatment groups were treated by co-culturing MSCs to PBMCs with a ratio of 1:10 (T1) and 1:1 (T2) for 48 h incubation. Furthermore, IFN-gamma and IL-10 levels were determined by cytometric bead array (CBA) fl ow cytometry.<br /><strong>Results</strong> <br />Hypoxic MSCs signifi cantly decreased the IFN-gamma levels and increased the IL-10 levels in dose-dependent manner<br />compared to the control group. The highest activity of hypoxic MSCs was noticed in T2 group.<br /><strong>Conclusion</strong> <br />Hypoxic MSCs- induced IL-10 are important in the control of anti-infl ammatory eff ect on SLE through inhibiting IFN-gamma. </p>

PSXIV-28 Post-Confluence Cell Age Affects Lipopolysaccharide-Induced Interleukin-8 Secretion in Ipec-J2 Cells

Abstract Porcine intestinal epithelial cell line IPEC-J2 is routinely used to investigate epithelial cell interactions with common enteric porcine antigens and pathogens. Lipopolysaccharides (LPS) are bacterial antigens metabolized from Gram negative bacteria that can induce a cellular inflammatory cascade, resulting in changes to cell structure and integrity, and are often used to challenge IPEC-J2 cells. Although numerous investigators employ the IPEC-J2 LPS model, consistent methodology regarding cell culture conditions and treatment times is not well defined. The objective of the current study was to determine the optimal post-confluence cell age for LPS induction of Interleukin-8 (IL-8) secretion and related cell integrity changes. For this study, cells were seeded at 2x104/cm2 in 24 well plates on day zero and incubated at 37°C, 5% CO2 for 3 days (confluence) prior to treatment in complete growth media (CGM) containing 5% fetal bovine serum. One day prior to treatment, CGM was removed and replaced with serum free (SF), phenol red-free media. On days 0, 5, 7, 12, 14 and 18 post confluence, cells were treated with LPS (0 or 10μg/mL) in SF and phenol red-free media for 24 hours. There were 5 replicates per treatment per timepoint. Lactate dehydrogenase (LDH) release, trans-epithelial electrical resistance (TEER), and IL-8 secretion were measured at each experimental timepoint. Data were statistically analyzed for the effect of time, treatment, and the subsequent interactive effect. There was no effect of treatment, time or their interaction on LDH release (P > 0.05), indicating cellular health was maintained over time and 10μg/ml LPS did not influence cellular toxicity. There was an effect of treatment, time and the respective interaction that showed IL-8 secretory responsiveness was increased with LPS challenge (P < 0.01), was increased on d 7 regardless of LPS challenge (P < 0.01) and peaked on d 5 post-confluence (P < 0.01). Furthermore, TEER was maximized at d 5 post-confluence and remained consistently greater relative to the d 0 baseline throughout the experiment (P < 0.01). These data indicate that LPS-induced IL-8 secretion and related cellular integrity are optimized at d 5 post-confluence in IPEC-J2 cells. In conclusion, in-vitro research utilizing the IPEC-J2 LPS model should allow cells to age 5 days post-confluence to maximize responses.

OR14-05 Taking Advantage Of The Interleukin-6-Biology In Differentiated Thyroid Cancer To Stimulate Sodium Iodide Symporter (NIS)-mediated Iodide Uptake In Engineered Mesenchymal Stem Cells

Abstract Disclosure: V.F. Koehler: Speaker; Self; Sanofi. L. Drago: None. M. Hageneier: None. C. Kitzberger: None. N. Schwenk: None. K. Shehzad: None. Y. Han: None. J. Nagarajah: None. P.J. Nelson: None. C. Spitzweg: None. Based on its role in mediating iodide uptake from the blood into thyroid follicular cells, the sodium iodide symporter (NIS) provides the basis for the use of radioiodine (RAI) for diagnostic imaging and therapy of differentiated thyroid cancer (DTC). The loss of functional NIS expression leads to RAI-refractory disease. The tumor-selective delivery of NIS as a transgene using mesenchymal stem cells (MSCs) represents a therapeutic strategy for RAI-refractory DTC. Interleukin-6 (IL-6) is a potent cytokine omnipresent in the inflammatory microenvironment of many solid tumors thought to sustain and promote tumor proliferation, invasion and angiogenesis, and contribute to immune escape. With the aim to selectively drive NIS-transgene expression in the context of DTC, MSCs were stably transfected with a NIS-expressing plasmid controlled by the human IL-6-promoter (IL-6-NIS-MSCs). This approach may represent a new tumor-target gene therapy for RAI-refractory DTC. To confirm the inducibility of the IL-6 promoter in IL-6-NIS-MSCs, the murine cytokines (IL-1 β, TNF-α, IFN-γ) were applied to stimulate promoter activation. The resulting functional NIS expression was analyzed by an 125Iuptake assay in vitro. The invitro IL-6 concentration in the papillary thyroid cancer cells BCPAP and K1either co-cultured with or without IL-6-NIS-MSCs was determined by ELISA. Subsequently, IL-6-NIS-MSCs were subjected to a gradient of serum free tumor cell conditioned medium (CM) and serum free unconditioned medium and its migratory response was assessed using 3D live-cell imaging migration assay.IL-6-NIS-MSCs treated with IL-1 β, IFN-γ and TNF-α revealed an increased125I uptake as compared to single stimulation studies. Asa basis for a future in vivo application, incubation of IL-6-NIS-MSC with CM of BCPAP and K1 containing diverse tumor-derived factors or directly co-cultured with these cell lines resulted in significant increase of 125I uptake as compared to untreated cells. The ELISA assay revealed high levels of IL-6 secretion in K1-CM andIL-6-NIS-MSCs co-cultured with BCPAP and K1, while a lower concentration was measured in BCPAP-CM. IL-6-NIS-MSCssubjected to a gradient between a serum free tumor cell-CM and serum free unconditioned medium, showed an increased migration towards tumor cell-CM over a period of 24 h. Taken together, our results indicate the feasibility of targeting IL-6 induction in the inflammatory-rich tumor environment of RAI-refractory DTC to re-establish functional NIS expression using engineered MSCs as delivery vehicles. These data also show us the potential of cytokine-induced promoters for driving NIS transgene expression for a novel imaging and theranostic NIS gene approach. Presentation: Friday, June 16, 2023